TY - JOUR
T1 - Optimizing the antihormonal treatment and prevention of breast cancer.
AU - Patel, Roshani R.
AU - Sharma, Catherine G.N.
AU - Jordan, V. Craig
N1 - Funding Information:
Supported by 5T32CA10365-03 (RRP) and by the Department of Defense Breast Program under award number BC050277 Center of Excellence (Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense) (VCJ), SPORE in Breast Cancer CA 89018 (VCJ), R01 GM067156 (VCJ), FCCC Core Grant NIH P30 CA006927 (VCJ), the Avon Foundation and the Weg Fund of Fox Chase Cancer Center (VCJ).
PY - 2007
Y1 - 2007
N2 - The incidence of breast cancer is rising throughout the world. Breast cancer is slowly becoming more prevalent in countries which previously had low rates of cancer as well as becoming a leading cause of cancer death in some countries. Fortunately, a large number of these tumors are estrogen receptor (ER) positive and respond to anti-hormonal adjuvant therapy which until recently has been 5 years of tamoxifen treatment. Unfortunately, a significant number of patients develop recurrent cancers and the recurrent tumors are resistant to tamoxifen treatment. In addition, because of tamoxifen's selective estrogenic actions, there have been reports of venous thrombosis, endometrial cancer, and strokes in patients receiving tamoxifen therapy. Thus, there are other novel therapies such as aromatase inhibitors that block estrogen production in postmenopausal women or fulvestrant that destroys the estrogen receptor. This paper will summarize the therapeutic options for anti-hormonal therapy, the role of anti-hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators.
AB - The incidence of breast cancer is rising throughout the world. Breast cancer is slowly becoming more prevalent in countries which previously had low rates of cancer as well as becoming a leading cause of cancer death in some countries. Fortunately, a large number of these tumors are estrogen receptor (ER) positive and respond to anti-hormonal adjuvant therapy which until recently has been 5 years of tamoxifen treatment. Unfortunately, a significant number of patients develop recurrent cancers and the recurrent tumors are resistant to tamoxifen treatment. In addition, because of tamoxifen's selective estrogenic actions, there have been reports of venous thrombosis, endometrial cancer, and strokes in patients receiving tamoxifen therapy. Thus, there are other novel therapies such as aromatase inhibitors that block estrogen production in postmenopausal women or fulvestrant that destroys the estrogen receptor. This paper will summarize the therapeutic options for anti-hormonal therapy, the role of anti-hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators.
UR - http://www.scopus.com/inward/record.url?scp=34748827491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748827491&partnerID=8YFLogxK
U2 - 10.2325/jbcs.966
DO - 10.2325/jbcs.966
M3 - Review article
C2 - 17485895
AN - SCOPUS:34748827491
SN - 1340-6868
VL - 14
SP - 113
EP - 122
JO - Breast cancer (Tokyo, Japan)
JF - Breast cancer (Tokyo, Japan)
IS - 2
ER -